Beryl Drugs Ltd. | Income Statement
Fiscal year is April-March. All values INR Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
144,645.80
132,325.30
130,217.80
109,556.80
159,869.00
Cost of Goods Sold (COGS) incl. D&A
131,470.80
119,661.20
120,254.90
94,442.20
104,132.00
Gross Income
13,175.00
12,664.10
9,963.00
15,114.60
55,737.00
SG&A Expense
8,331.40
10,083.30
8,015.20
13,346.70
42,137.00
EBIT
4,499.30
2,213.50
1,052.00
1,102.40
13,600.00
Unusual Expense
178.80
350.80
856.30
-
-
Non Operating Income/Expense
514.30
882.50
1,010.60
1,547.30
-
Interest Expense
1,883.20
2,608.90
2,054.70
2,008.50
1,323.00
Pretax Income
4,290.10
1,345.80
2,455.90
1,701.20
12,277.00
Income Tax
1,621.50
501.50
790.30
535.20
2,348.00
Consolidated Net Income
2,668.60
844.30
1,665.60
1,166.10
9,929.00
Net Income
2,668.60
844.30
1,665.60
1,166.10
9,929.00
Net Income After Extraordinaries
2,668.60
844.30
1,665.60
1,166.10
9,929.00
Net Income Available to Common
2,668.60
844.30
1,665.60
1,166.10
9,929.00
EPS (Basic)
0.53
0.17
0.33
0.23
1.96
Basic Shares Outstanding
5,071.70
5,071.70
5,071.70
5,071.70
-
EPS (Diluted)
0.53
0.17
0.33
0.23
-
Diluted Shares Outstanding
5,071.70
5,071.70
5,071.70
5,071.70
-
EBITDA
7,693.70
7,374.30
5,152.80
4,878.60
16,897.00
Other Operating Expense
344.20
367.30
895.70
665.60
-
Non-Operating Interest Income
1,338.50
1,209.50
1,591.70
1,060.10
-
About Beryl Drugs
View Profile
